

Published in final edited form as:

Toxicol. 2011 July ; 58(1): 35–45. doi:10.1016/j.toxicol.2011.04.020.

Hemostatic and toxinological diversities in venom of *Micrurus tener tener*, *Micrurus fulvius fulvius* and *Micrurus isozonus* coral snakes

Ana M. Salazar^a, Jeilyn Vivas^a, Elda E. Sánchez^b, Alexis Rodríguez-Acosta^{c,d}, Carlos Ibarra^a, Amparo Gil^a, Zoila Carvajal^a, María E. Girón^{c,d}, Amalid Estrella^{c,d}, Luis F. Navarrete^c, and Belsy Guerrero^{a,*}

^aLaboratorio de Fisiopatología, Centro de Medicina Experimental, Instituto Venezolano de Investigaciones Científicas (IVIC), Apartado 20632, Caracas 1020A, Venezuela

^bDepartment of Chemistry and The National Natural Toxins Research Center, Texas A & M University-Kingsville, Kingsville, TX 78363, USA

^cSección de Inmunoquímica, Instituto de Medicina Tropical de la Universidad Central de Venezuela, Caracas, Venezuela

^dLaboratorio de Inmunoquímica y Ultraestructura, Instituto Anatómico de la Universidad Central de Venezuela, Caracas, Venezuela

Abstract

The coral snake *Micrurus tener tener* (*Mtt*) from the Elapidae family inhabits the southwestern United States and produces severe cases of envenomations. Although the majority of *Mtt* venom components are neurotoxins and phospholipase A₂s, this study demonstrated, by SDS-PAGE and molecular exclusion chromatography (MEC), that these venoms also contain high-molecular-weight proteins between 50 and 150 kDa that target the hemostatic system. The biological aspects of other *Micrurus* venoms were also studied, such as the LD₅₀s of *Micrurus isozonus* (from 0.52 to 0.61 mg/kg). A pool from these venoms presented a LD₅₀ of 0.57 mg/kg, *Micrurus f. fulvius* (*Mff*) and *Mtt* had LD₅₀s of 0.32 and 0.78 mg/kg, respectively. These venoms contained fibrino(geno)lytic activity, they inhibited platelet aggregation, as well as factor Xa and/or plasmin-like activities. *M. isozonus* venoms from different Venezuelan geographical regions inhibited ADP-induced platelet aggregation (from 50 to 68%). *Micrurus tener tener* venom from the United States was the most active with a 95.2% inhibitory effect. This venom showed thrombin-like activity on fibrinogen and human plasma. Fractions of *Mtt* showed fibrino(geno)lytic activity and inhibition on plasmin amidolytic activity. Several fractions degraded the fibrinogen A α chains, and fractions F2 and F7 completely degraded both fibrinogen A α and B β chains. To our knowledge, this is the first report on thrombin-like and fibrino(geno)lytic activity and plasmin or factor Xa inhibitors described in *Micrurus* venoms. Further purification and characterization of these *Micrurus* venom components could be of therapeutic use in the treatment of hemostatic disorders.

© 2011 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: + 58 212 5041180; fax: + 58 212 504 1086. bguerrer@ivic.gob.ve, belsyguerrero@yahoo.es (B. Guerrero).

Conflict of interest

The authors declare no conflicts of interest.

Keywords

Coral snakes; Fibrino(geno)lytic activity; Hemostasis; *Micrurus tener tener*; Plasmin inhibitors; Platelets; Venom

1. Introduction

Venoms of the Elapidae family could produce hemorrhagic effects, which have not been thoroughly studied since these bites rapidly produce severe symptoms of neurotoxicity when humans are envenomated. Snake venoms are a diverse mixture of enzymatic and non-enzymatic toxins with an ample range of molecular masses between 15 and 380 kDa (Kini and Evans, 1992). Proteases are commonly found in venom at high concentrations and can be classified into two groups: serine proteases and metalloproteases. Several serine and metalloproteases have been well characterized, especially from viperid and crotalid venoms (Maruyama et al., 1992; Zaganelli et al., 1996; Aguilar et al., 2001; Salazar et al., 2007). A number of metalloproteases from the Elapidae venom are fibrin(ogen)ases (Jagadeesha et al., 2002) or factor V activators (Gerads et al., 1992). Proteases are not the only type of venom molecules that affect hemostatic components; for instance, the three-finger toxins from the Ringhals cobra venom inhibits factor VIIa (Banerjee et al., 2005). Furthermore, various venom phospholipase A₂ (PLA₂s) have also been described as anticoagulants (Kini, 2005).

Coral snakes represent a taxonomic assembly of more than 120 species and subspecies found throughout the Southern United States, Central and South America with their maximum diversity close to the equator (Roze, 1996). The active components of only a few species have been investigated (Gutiérrez et al., 1991; de Roodt et al., 2004; Suntravat et al., 2010). The Texas coral snake, *Mtt* is a small venomous snake inhabiting the southwestern United States which contains potent neurotoxic venom. Even though most of the venom components are neurotoxins and/or PLA₂s, our study has demonstrated that it also contains high-molecular-weight (between 40 and 150 kDa) proteins targeting the hemostatic system.

This work demonstrated several hemostatic and biological activities found in *Mtt* venom, one of the venoms of important medical interest in the United States of America. To our knowledge, severe hemostatic activities in *Mtt* have not been described in the literature.

2. Materials and methods

2.1. Reagents

The Superdex-200 10/300 GE chromatographic separation column was purchased from GE Healthcare (Piscataway, NJ, USA). Chromogenic substrates were purchased from Anlara (Mason, OH, USA). Molecular weight standards were purchased from Invitrogen, (Carlsbad, CA, USA). Purified substrates factor Xa, bovine alpha thrombin, plasmin, and human fibrinogen were purchased from American Diagnostica Inc. (Stamford, CT, USA). ADP was from Chronolog Corp, (Havertown, PA, USA). Thrombin standards were from the National Institute for Biological Standards and Control (NIBSC, UK). Aprotinin was purchased from Bayer (Leverkusen, Germany). Bovine alpha thrombin, benzamidine/HCl, ethylene glycol-bis(2-aminoethylether)-*N, N, N', N'*-tetraacetic acid (EGTA), ethylenediaminetetraacetic acid (EDTA), iodoacetic acid and other reagents used in this study were from Sigma Chemical Co (St. Louis, MO, USA).

2.2. Venoms

Pools of venoms from *Mtt* and *Mff* (Texas and Florida coral snakes, respectively) were purchased from the National Natural Toxins Research Center, Texas A&M University-Kingsville, Texas, USA. The lyophilized pool included venom from approximately 10 specimens from snakes found in the south Texas (*Mtt*) and approximately 20 specimens found in Osceola Co., Florida (*Mff*). The venoms were stored at -80°C .

Micrurus venoms from snakes captured in diverse Venezuela geographical locations were represented by a pool from at least eight different specimens. These snakes include *Micrurus isozonus* from Calabozo (Guárico state), Caracas (Capital District), La Boyera (Miranda state) and Maracay (Aragua state), Venezuela. The snakes are currently housed in the Serpentarium of the Institute of Tropical Medicine of the Universidad Central de Venezuela. The venoms were obtained by extracting once from each animal into sterile Petri dishes, then lyophilized, divided into 5 mg samples and kept at -80°C until use.

2.3. Animals

Female BALB/c mice weighting 18–22 g were obtained from the Animal House of the Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas, Venezuela and maintained at $22\text{--}24^{\circ}\text{C}$, with a relative humidity of 45–70%, and a 12-h light/dark cycle (lights on at 07.00 h). Mice were acclimated at least 1 week prior to each experiment and received water and food *ad libitum*. The Animal House authorities' surveillance reports established that the mice were free of known pathogenic bacteria, viruses, mycoplasmas, and parasites.

2.4. Ethical statement

All the experimental procedures regarding the use of live animals were done by specialized personnel according to the Venezuelan pertinent regulations and institutional guidelines approved by the Animal Bioethics Commissions of the Instituto Venezolano de Investigaciones Científicas and the Institute of Anatomy of the Universidad Central de Venezuela. The norms were obtained from the guidelines for the care and use of laboratory animals published by the United States National Institute of Health (NIH, 1985).

2.5. Protein concentration determination

The protein concentration of crude venoms was measured by the method of Lowry et al. (1951) and spectrophotometrically estimated by assuming that 1 unit of absorbance/cm of path length at 280 nm corresponds to 1 mg protein/ml (Stoscheck, 1990).

2.6. SDS-PAGE

Polyacrylamide gel electrophoresis of *Mtt* venom was carried out on a 10–20% Tricine gel using an XCell Sure-Lock[®] system (Invitrogen, Carlsbad, CA). A total of 22 μg of non-reduced and reduced crude venom were run at 125 V for 90 min. The gel was stained with Simply Blue Safe stain (Invitrogen).

2.7. Molecular exclusion chromatography

Micrurus t. tener venom was fractionated by molecular exclusion chromatography on a Superdex-200 10/300 column equilibrated with 50 mM ammonium acetate buffer, pH 6.9. The venom sample (5 mg/100 μl) was resuspended in equilibrium buffer and injected into the column. The elution was carried out with the same buffer at a flow rate of 0.4 ml/min and monitored at 280 nm using a Waters 2487 high performance liquid chromatography (HPLC) system.

2.8. *Micrurus* venoms lethality

Lethality of crude venom was determined by intravenous injections into mice and the LD₅₀ value calculated according to Spearman-Kärber method (WHO, 1981). The venom was diluted in phosphate-buffered saline solution (PBS). The endpoint of lethality of the mice was determined after 48 h. All solutions throughout the experiments were stored at 4 °C and warmed to 37 °C immediately prior to being injected into mice. The lethal toxicity was determined in five groups containing five mice. A total of 0.2 ml of venom (dosages from 0.03 to 1.9 mg/kg) was injected into the tail vein of 18–20 g female BALB/c mice. An equivalent volume of PBS was injected as a negative control group.

2.9. The effects of *Micrurus* venoms on platelet aggregation

Platelet aggregation was estimated by turbidimetry using a dual-channel Chronolog model 560 CA aggregometer. Platelet-rich plasma (PRP) was prepared by mixing fresh blood sample with trisodium citrate solution (3.8%, w/v) in a volume ratio of 9:1, followed by centrifugation at $190 \times g$, 24 °C for 20 min to sediment leukocytes and erythrocytes. The platelet count was adjusted to 3.0×10^5 platelets/ μ l with platelet-poor plasma. Four hundred ninety microliters of citrated PRP were pre-incubated at 37 °C with a stir bar in a silicone-treated glass cuvette. Then, 10 μ l/10 μ g of crude venom or fractions dissolved in PBS and PBS alone was added 4 min prior to the addition of the platelet aggregation inducer. Aggregation was induced by adding 5 μ l of adenosine diphosphate (ADP) (final concentration of 10 μ M), and the changes in light transmittance were continuously recorded for 8 min. The maximum aggregation response obtained after the addition of an inducer in the absence of crude venom or fractions was taken as 100% aggregation. The inhibition percentage was calculated by comparing light transmittance obtained in presence of venom against the control sample. The IC₅₀ value was calculated from a dose-dependent curve that was achieved from at least five different venom concentrations using the software program Graph Pad Prism.

2.10. Coagulant activity of *Micrurus* venoms

Procoagulant activity in *Micrurus* Spp. venoms was determined by the method adapted from Salazar et al. (2007). In a borosilicate tube (10 \times 75 mm), 0.1 ml of 0.05 M Tris-HCl buffer, pH 7.4 (coagulation buffer) containing 0.1 ml venom samples (1–50 μ g, diluted in coagulation buffer) was incubated at 37 °C. Then 0.1 ml of fresh citrate human plasma or 0.3% of human fibrinogen solution in coagulation buffer was added. The solution was mixed thoroughly and the coagulation time recorded. All experiments and appropriate controls were repeated at least four times.

2.11. Amidolytic activity of *Micrurus* venoms

The *Micrurus* Spp. venoms were evaluated for amidolytic activity using a micro-method standardized in our laboratory (Guerrero and Arocha-Piñango, 1992). A mixture of 80 μ l of the recommended buffer for each chromogenic substrate, 10 μ l of the venom sample (2 mg/ml) and 10 μ l of substrate (final concentrations of 0.60 mM S-2238, 1.20 mM S-2288, 0.16 mM S-2586, 0.80 mM S-2222, 0.80 mM S-2251, 0.44 mM S-2302 or 0.16 mM S-2444) were placed in each well of 96 well polystyrene plates. Bovine thrombin, bovine factor Xa, urokinase-PA and plasmin were used as positive controls. After incubation at 37 °C for 15 and 30 min, the absorbance at 405 nm was measured. One unit of amidolytic activity was expressed as ΔA 405 nm/min. Specific activity was calculated as mUA/min/ μ g.

2.12. The effects of *Micrurus* venoms on thrombin, factor Xa or plasmin activities

The effects of *Micrurus* Spp. venoms on thrombin, factor Xa or plasmin amidolytic activity was evaluated by the micro-method described above. Briefly, in polystyrene plates of 96

wells, 10 μ l of *Micrurus* venom (20 μ g) were mixed with 20 μ L of the enzyme (0.25 nKcat plasmin, 0.1 IU thrombin or 0.05 IU factor Xa), and incubated for 30 min at 37 °C. Then 60 μ l of the recommended buffer solution for each substrate and 10 μ l of chromogenic substrate were added. After incubation at 37 °C for 10 min, the absorbance at 405 nm was measured. The enzymes incubated with buffer were used as controls, which measured 100% activity.

2.13. Effect of *M. t. tener* venom on factor Xa and thrombin coagulant activity

Anticoagulant activity of *Mtt* venom on factor Xa and thrombin was also evaluated using the Salazar et al. (2007) method. Factor Xa (0.05 IU/mL) or thrombin (2.5 IU/mL) was incubated at 37°C for 30 min with 0.1 ml of venom sample (1–25 μ g). Then the residual coagulant activity was evaluated for factor Xa using fresh citrate human plasma in presence of 0.025 M CaCl₂ and for thrombin using fresh citrate human plasma or human fibrinogen solution (0.3% in coagulation buffer). All experiments and appropriate controls were repeated at least four times.

2.14. Fibrinolytic activity of *M. t. tener* venom

Fibrinolytic activity of *Mtt* venom was studied by the fibrin plate method as described by Marsh and Arocha-Pinango (1972). Fibrin plates were made using 3-cm diameter Petri dishes by allowing 1.5 ml of fibrinogen solution (10% plasminogen as contaminant, 0.1% in 5 mM imidazol saline buffer, pH 7.4) to clot by adding 75 μ l of bovine thrombin (10 IU/ml, in 0.025 M CaCl₂). The mixture was incubated at 22–25 °C for 30 min, and then 10 μ l (25–50 μ g) of sample was applied over the fibrin. After 24 h incubation at 37 °C, the fibrin hydrolysis diameter (lysed area) was measured. The activity was then recorded as the lysis area consisting of the maximum and smallest size diameter, which could be measured at right angles, and this was expressed in mm². Specific fibrinolytic activity (mm²/ μ g) was calculated dividing the lysed area (mm²) by the given protein dose (μ g). Human plasmin (0.25 nKcat) was used as positive control.

2.15. The effects of *M. t. tener* venom on plasmin fibrinolytic activity

The effects of *Mtt* venom and chromatographic fractions on plasmin fibrinolytic activity were tested by a modification of the method described by Marsh and Arocha-Pinango (1972). Fibrin films were formed in wells of a 96 well polystyrene plate: 200 μ l of fibrinogen (0.1%) was allowed to clot with 12 μ l of bovine thrombin (10 IU/ml, in 0.025 M CaCl₂). The mixture was incubated at 22–25 °C for 60 min. The venom's effect on plasmin fibrinolytic activity (0.25 nKcat) was tested after pre-incubating plasmin with 10 μ l of crude venom (20 μ g) at 37 °C for 30 min and then applying it to the fibrin for 6 h at 37 °C. The assay was also carried out with crude venom pre-treated with serine protease (10 mM benzamidine and 100 IU/ml aprotinin), metalloprotease (10 mM EDTA), or cysteine protease (iodoacetic acid 10 mM) inhibitors (CPI). As controls, the fibrinolytic activity with plasmin (0.25 nKcat), *Mtt* venom (20 μ g), and chromatographic fractions (20 μ g) was tested on the fibrin film. After the 6 h incubation period, the absorbance was measured at 405 nm. The effect of *Mtt* venom on plasmin fibrinolytic activity was expressed as the change in absorbance of the fibrin film.

2.16. Statistical analysis

All experiments were repeated three times. Results were expressed as the mean \pm standard deviation and analyzed using the two-tailed Student's *t*-test for samples with equal variances. Differences were statistically significant if *p* was less than 0.05.

3. Results

3.1. SDS-PAGE analysis of *M. t. tener* venom

The electrophoretic profile of crude *Mtt* venom was analyzed by SDS-PAGE in a gradient of 10–20% (Fig. 1). Under non-reduced conditions, 17 well-defined venom protein bands were observed. Two were observed between 45 and 55 kDa, one between 34 and 45 kDa, 12 bands between 18 and 7 kDa, and two between 4 and 7 kDa.

3.2. Chromatographic profile of *M. t. tener* venom

Sixteen *Mtt* venom fractions were collected (F1 to F16) from a Superdex-200 10/300 molecular exclusion column (Fig. 2). Fractions 1 to 5, having very low concentrations and elution times between 12 and 34 min, are shown in the insert of Fig. 2. Fractions F7 to F14 had the highest protein concentrations. The molecular weights for the proteins in F6 to F10 ranged from 75 to 5 kDa, and F2, which contained a very low protein concentration, had proteins at 150 kDa.

3.3. *Micrurus* venoms lethality

The LD₅₀ values, determined by probit analysis at 95% confidence, showed differences among the *Micrurus* venoms tested. The most potent venom (Table 1) was *Mff* from Florida, USA (0.32 mg/kg), and *Mtt* from Texas, USA was the least active (0.78 mg/kg). The *M. isozonus* venoms showed LD₅₀s ranging from 0.52 to 0.61 mg/kg. A pool of these *M. isozonus* venoms presented a LD₅₀ of 0.57 mg/kg.

3.4. The effect of *Micrurus* venoms on platelet aggregation

The effects of *Micrurus* venoms on ADP-induced platelet aggregation are displayed in Table 2. *Micrurus* venoms inhibited 50–95% of ADP-induced platelet aggregation. *Micrurus isozonus* venoms from different Venezuelan geographical regions (10 µg) inhibited platelet aggregation from 50 to 68.2%, with the Capital District venom having the highest effect (68.2%). *Micrurus t. tener* was the most active with a 95.2% inhibitory effect. The results showed that this crude venom inhibited ADP-induced platelet aggregation with an IC₅₀ of 12.79 µg/ml.

Chromatography fractions of *Mtt* venom (10 µg) were also evaluated. Fractions F1, F2, F6 to F8 and F11 to F16 inhibited platelet aggregation by more than 60% (Table 3). However, the highest inhibitory activity (>80%) was observed in fractions F2, F11 and F13 to F15.

3.5. Coagulant activity of *Micrurus* venoms

Micrurus Spp. venoms obtained from diverse geographical Venezuelan and USA locations did not have significant procoagulant activity on plasma or on fibrinogen doses between 20 and 50 µg. However, *Mtt* venom at doses between 1 and 10 µg induced the formation of an instable fibrin gel at 25–30 s incubation time.

3.6. Amidolytic activity of *Micrurus* venoms

All *Micrurus* crude venoms did not have significant thrombin, factor Xa, or plasmin-like activities using amidolytic methods at doses up to 20 µg. Additionally, when fresh citrated human plasma was incubated 10 min with the venoms, no effect was observed when kallikrein, factor Xa or thrombin chromogenic substrates were used. These results indicated that the venoms, under such conditions, did not exhibit pre-kallikrein, factor X or prothrombin activators, as well as thrombin-like amidolytic activity.

3.7. The effects of *Micrurus* venoms on factor Xa, thrombin and plasmin amidolytic activities

The effects of *Micrurus* crude venoms (20 µg) on plasmin (0.25 nKcat), thrombin (0.1 IU) and factor Xa (0.05 IU) amidolytic activities are shown in Table 4. All the crude venoms tested inhibited plasmin amidolytic activity on S-2251 chromogenic substrate between 40 and 99%. All the *M. isozonus* venoms produced diverse effects. For instance, *M. isozonus* of the Capital District inhibited plasmin (98.5%) by almost twice as much as the venoms of La Boyera, Guárico, and Aragua states (~50%). *Micrurus t. tener* venom was more active than *Mff* venom having 71 and 40% inhibitory activities, respectively.

In reference to factor Xa amidolytic activity, *M. isozonus* venoms produced minimal inhibition values ranging from 16.5 to 21.6%. *Micrurus t. tener* and *Mff* venoms did not inhibit factor Xa amidolytic activity. Regarding thrombin amidolytic activity, all *M. isozonus* venoms showed limited inhibitory effects. *Micrurus t. tener* and *Mff* venoms did not inhibit thrombin amidolytic activity.

Studies with the *Mtt* chromatographic fractions (20 µg) demonstrated that F2, F5 to F9 and F13 to F15 induced a significant inhibition of plasmin amidolytic activity, with the most active fractions being F6, F8 and F14 with inhibitory activities from 75 to 82% (Table 3).

3.8. Fibrinogenolytic activity of *Micrurus t. tener* venom

The study of *Mtt* crude venom on fibrinogen demonstrated that the fibrinogen:venom ratios of 100:1, 100:5 and 100:10, incubated for 4 h, induced fibrinogen A α chain degradation, generating fragments with diverse molecular masses (data not shown). The results using a 100:1 ratio at different times demonstrated that the proteases present in *Mtt* venom induced a rapid degradation of fibrinogen A α chains (1 h) and a slower degradation of B β chains (18 h). It was also observed that the A α chains degradation started at 5 min, with a maximum at 1 h, and degradation of B β chains was from 18 to 24 h, and full degradation was observed at 24 h. The γ chains were unaffected (Fig. 3A). This fibrinogenolytic activity was completely inhibited by metalloprotease, and cysteine protease inhibitors (iodoacetic acid), while the serine protease inhibitors did not modify the degradation pattern (Fig. 3B).

Fig. 4A shows the fibrinogenolytic activity of the *Mtt* venom fractions at a 100:1 (Fg:venom) ratio and 24 h incubation. Fractions F1–F4 and F6–F8 degraded the A α chains with different intensities. Fractions F2 and F7 completely degraded both fibrinogen A α and B β chains. The γ chains were not affected by the fractions.

The fibrinogenolytic activities of the fractions were also evaluated in presence of protease inhibitors. The results showed that the proteolytic activity of fractions F1, F3, F4, F6 and F8 was completely inhibited only by MPI, while the activity of fractions F2 and F7 was partially inhibited by EDTA, SPI and iodoacetic acid. The fibrinolytic activity of F2 and F7 fractions was completely inhibited by MPI and SPI. Fig. 4B shows the results obtained with F3 and F7 fractions in presence or absence of protease inhibitors.

3.9. Fibrinolytic activity of *Micrurus t. tener* venom

The fibrinolytic activity of *Mtt* venom at different doses was evaluated on plasminogen-rich fibrin plates. Plasmin (0.25 nKcat), used as a positive control, produced a fibrin lysis area of 418 mm² (Fig. 5A). Twenty-five micrograms of *Mtt* showed a fibrin lysis area of 16 mm² with a central white halo, which could indicate the presence of a plasmin inhibitor(s) present in the crude venom (Fig. 5B). At 50 µg, *Mtt* venom had a fibrin lysis area of 100 mm² and an increase in the diameter of the white halo (Fig. 5C).

The fibrinolytic activity of the chromatographic fractions (20 µg) obtained from *Mtt* venom was evaluated on fibrin film using a micro-method. The results revealed that F1 to F4 and F7 and F8 contained fibrinolytic activity (Table 3).

3.10. The effect of *M. t. tener* venom on plasmin fibrinolytic activity

The fibrin film in presence of a buffer control showed an absorbance of 0.4348 ± 0.0195 at 405 nm. The fibrin incubated with plasmin (0.25 nKcat) during 6 h presented an absorbance of 0.1753 ± 0.0335 ($p < 0.001$), which denoted a 59.58% decrease in optical density (OD), representing 100% lysis. The fibrin incubated with *Mtt* crude venom (20 µg) presented an absorbance of 0.3716 ± 0.0237 ($p < 0.01$), which represented a 15.15% decrease in OD and a lysis of 24.3%. The fibrin incubated with plasmin (0.25 nKcat) pre-treated with *Mtt* crude venom (20 µg) presented an absorbance of 0.0961 ± 0.0331 ($p < 0.001$), which indicated a 77.9% decrease in OD and a 130% lysis, representing complementary fibrinolytic activity with both plasmin and venom (Fig. 6).

The pre-treatment of the *Mtt* crude venom with proteases inhibitors showed that only benzamidine significantly inhibited fibrin lysis induced by plasmin and venom (Fig. 6).

3.11. The effect of *M. t. tener* venom on factor Xa and thrombin coagulant activity

Table 5 shows that *Mtt* venom inhibits factor Xa coagulant activity in a dose-dependent manner, an effect evidenced by the increase in coagulation time of this enzyme pre-treated with crude venom using as substrate citrated human plasma in presence of calcium. In contrast, this venom increases, in a dose-dependent manner, the thrombin coagulant activity, which was evidenced by the decrease in coagulation time of this enzyme pre-treated with crude venom.

4. Discussion

Elapidae venoms are described as complex mixtures containing protein components with neurotoxic functions that can cause alterations in the nervous system, and many also contain hemorrhagic components, which induce alterations of the capillaries (Rosso et al., 1996; Markland, 1998; Wijeyewickrema et al., 2007). Several Elapidae snake venoms with neurotoxic activity, such as the cobras (Elapidae), also contain proteins that activate or inhibit the hemostatic system (Utkin and Osipov, 2007; Osipov et al., 2010). For instance, a metalloprotease enzyme capable of activating factor V was described in the venom of *Naja naja oxiana* (Gerads et al., 1992). Other elapids, Australians for example, showed that their hemostatic activities were limited to prothrombin activation and contain no thrombin-like enzymes (Chester and Crawford, 1982; Fry, 1999; Braud et al., 2000; Matsui et al., 2000; Rao et al., 2003). St Pierre et al. (2005) described from the cDNA gland of Australian elapids, two prothrombin activators, factor X and factor V- like.

The isolation and characterization of coral snake venom components have not been well documented to date. In this study we have evaluated the biochemical and biological characteristics, in regards to coagulation, fibrinolysis and platelet functions, of several venoms of the *Micrurus* genus, with particular reference to *Mtt* venom.

Micrurus snakes belonging to the Elapidae family are the most representative genus in respect to abundance and diversity, with a great number of species found in South America and the Southern United States. Coral snake envenomations are comparatively infrequent because of their subfossorial behavior and the high incidence of dry bites; nevertheless, the mortality attributed to muscle respiratory paralysis is high (Rengifo and Rodríguez-Acosta, 2004). In spite of being considered amongst the most toxic snakes in America (Roze, 1996), their venom hemostatic activities have been scarcely described since disorders of blood

coagulation are not common in human envenomations (Barros et al., 1994; Francis et al., 1997; Urdaneta et al., 2004; Cecchini et al., 2005; Dokmetjian et al., 2009).

Several biological activities have been demonstrated in comparative studies among venoms from several *Micrurus* taxa (Gutiérrez et al., 1983, 1992; Aird and da Silva, 1991; Alape-Girón et al., 1994; Barros et al., 1994). Lethality studies in mice are utilized as a direct evaluation of the pathological action of general venom toxicity. In the current work, the LD₅₀ values of the three *Micrurus* venoms were shown to be different. The most lethal was *Mff* venom (0.32 mg/kg) followed by *M. isozonus* (averaging 0.57 mg/kg), and then *Mtt* (0.78 mg/kg). These results are in accordance with those reported by other authors (Arce et al., 2003; Sánchez et al., 2008) who studied the lethal toxicities of *Mff* (LD₅₀ = 0.32 mg/kg) and *Mtt* (LD₅₀ = 0.78 mg/kg).

Some snake venom components are recognized as modulators of platelet receptors and their ligands. The platelets play a crucial function in hemostasis, but in addition are liable for the pathogenic thrombosis triggering severe clinical manifestations of vascular atherothrombotic disease (Varon et al., 2009; Fabre and Gurney, 2010). Several authors have proposed that snake venoms of the family Elapidae are capable of inhibiting platelets aggregation through the action of L-amine oxidases or phospholipases A₂ (Rosso et al., 1996; Alape-Girón et al., 1999; Sakurai et al., 2001; Satish et al., 2004). Moreover, Oyama and Takahashi (2007) evaluated the effects of venom from 11 species of the Elapidae family on platelet aggregation, specifically inhibiting platelet aggregation induced by ADP. In the present study, it was demonstrated that three *M. isozonus* venoms (10 µg) from snakes captured in diverse Venezuelan localities as well as venoms from *Mtt* and *Mff*, both from the USA (10 µg), exhibited an inhibition of ADP-induced platelet aggregation, with *M. t. tener* venom displaying the highest activity (95.2% inhibitory effect). This effect could be related to disintegrin-like components, or to the proteolytic effects against ADP receptors or to the presence of ADPases. In future studies the possible mechanism of action with isolated fractions of these toxins will be evaluated.

Although no significant coagulopathy has been reported in Elapidae venoms, the cobra (*N. naja*) induces blood clots *in vitro* by activating prothrombin, as demonstrated by thrombin-specific chromogenic substrates (Sundell et al., 2003). In our study, none of the *Micrurus* venoms presented a significant factor Xa, thrombin or chymotrypsin-like amidolytic activities. These results suggested the absence of a significant procoagulant activity related to prothrombin or factor X activators. In contrast, *Mtt* at very low doses (between 1 and 20 µg) pre-incubated with purified fibrinogen induced an instable fibrin gel formation, which evidence a thrombin-like coagulant activity in *Mtt* venom. The fibrinogenolytic activity present in this venom probably masked this thrombin-like coagulant activity, which should not activate factor XIII, given that the formed fibrin gel is unstable.

Several biochemical and hemostatic characteristics from *Mtt* venom were analyzed. Electrophoretic analysis evidenced venom components with molecular masses of 130 kDa. Several venom components in *Mtt* venom were between 64 and 50 kDa, which is uncommon since neurotoxins are mostly of low molecular weights (Tanaka et al., 2010). After gel electrophoresis analysis, *M. t. tener* venom was fractionated by molecular exclusion chromatography in order to isolated fibrinogenases and fibrinolytic enzymes as well as anti-plasmin inhibitors. *Micrurus t. tener* venom chromatographic profiles showed 16 fractions (Fig. 2). The first fractions showed very low absorbencies at 280 nm (F1 to F4) corresponding to proteins of high molecular masses (>75 kDa), which contained fibrinogenolytic activity as well as inhibitory effects on the plasmin amidolytic activity and on ADP-induced platelet aggregation, which can all be related to metalloproteases activities. Additionally there is a group of proteins with molecular masses between 75 and 12 kDa (F6

to F9) where these activities are also present. The molecular masses around 26 kDa are in the same range of metalloproteases such as those described in various venoms (Bjarnason and Fox, 1994; Markland, 1998). This is also the molecular weight ranges (26–13 kDa) in which serine proteases with hemostatic activities such as Bothrombin (Nishida et al., 1994) and Bothrojaracin (Zingali et al., 1993) have been described.

The *Micrurus* venoms have also been characterized as possessing low or non-proteolytic activity. The presence of hyaluronidase activity was demonstrated in several *Micrurus* species from different geographic Brazilian locations and one Northern American species (*Mff*) (Tanaka et al., 2010). Fibrinogenolytic activity tested with *Mtt* crude venom showed that the fibrinogen A α chains was hydrolyzed much earlier than the B β -chains, while the γ -chain remained resistant to proteolysis even after 24 h. The α -fibrinogenases enzymes specifically degraded the A α chains and are metalloproteases, they also cleave the B β -chains but at a slower rate (Markland, 1998; Swenson and Markland, 2005). Alpha-fibrinogenases have been isolated from the venoms of *Bothrops* (Maruyama et al., 1992), *Agkistrodon* (Moran and Geren, 1981), and *Cerastes* (Daoud and Tu, 1986) among others.

The F1, F3, F4, F6 and F8 fractions induced degradation of fibrinogen A α chains, which was inhibited with metal chelating agents signifying that these toxins were mainly metalloproteases. In contrast, F2 and F7 fractions induce degradation of both fibrinogen A α and B β -chains, which were partially inhibited by metallo- and serine proteases inhibitors, which demonstrated that these fractions contained both serine and metalloproteases activities. These results were in accordance with Jagadeesha et al. (2002) who isolated and characterized a non-toxic anticoagulant metalloprotease, (NN-PF3; 67.81 kDa), from *N. naja naja* venom with strong anticoagulant and fibrinogenolytic activities. Gowda et al. (2006) also demonstrated that the fibrinogenolytic activity of *N. naja* venom was due to metalloproteases.

Venoms may cause fibrin degradation due to some serine proteases which directly degrade fibrin in a plasmin-like manner (Zhang et al., 1995; Kamiguti et al., 1996; Cho et al., 2004; Swenson and Markland, 2005). Furthermore, the fibrinolytic activity of *Mtt* venom at different doses was evaluated on plasminogen-rich fibrin plates, and showed a fibrin lysis area as well as a white halo, which could be indicating the presence of plasmin inhibitor(s) or plasminogen activator inhibitor(s) in the crude venom. Furthermore, the plasmin activity (enzyme that physiologically degrades fibrin) evaluated by a fibrin lysis micro-method was significantly increased in presence of *Mtt* crude venom (Fig. 6), which confirmed the fibrinolytic activity presence in this venom.

To corroborate the presence of plasmin inhibitor(s) in *Mtt* venom, the plasmin amidolytic activity was evaluated. The results demonstrated that the plasmin amidolytic activity (S-2251) was significantly inhibited (between 40 and 99%) in the presence of all *Micrurus* sp venoms tested. *M. isozonus* venom (Caracas) was the most active (99%), followed by *M. t. tener* (71%) (Table 4). These results revealed that *Micrurus* venoms also contain plasmin inhibitors.

Additionally, *Mtt* fractions were used to evaluate plasmin inhibitors. The results showed that F2, F5 to F9 and F13 to F15 fractions induced an inhibition of the plasmin amidolytic activity. Fractions F6, F8 and F14 were the most active, showing inhibitory effects as high as 75%. The inhibition effect on plasmin amidolytic activity can be associated with inhibitory molecules or with proteolytic activity against the plasmin molecule. These results stimulate future studies with the isolation and characterization of plasmin inhibitor(s); for instance, plasmin inhibitors can be used as potential anti-fibrinolytic components in hemophilia and/or local surgical procedures such as dental extractions. Snake venoms from

N. naja naja and *Pseudonaja textilis textilis* (Textilinins) have been accounted to contain plasmin inhibitory toxins. Textilinins, a Kunitz-type serine protease inhibitor with a high specificity for plasmin, showed homology with aprotinin and was capable of inhibiting hemorrhages in experimental mice (Takahashi et al., 1974; Ritonja et al., 1983; Masci et al., 2000; Millers et al., 2009).

Few anticoagulant components have been described in Elapids (Kini and Evans, 1991; Sundell et al., 2003; White, 2005; Gowda et al., 2006; Kumar et al., 2010). A protein complex, the hemextin AB, was isolated from the *Hemachatus haemachatus* (African Ringhals cobra) venom, which is an inhibitor of factor VIIa (Banerjee et al., 2005). Recently, the venom of *Naja pallida* was also shown to contain anticoagulant activity (Suntravat et al., 2010). A basic phospholipase A₂ (CM-IV) was isolated from *Naja nigricollis* venom which inhibited the prothrombinase complex by a novel non-enzymatic mechanism (Stefansson et al., 1990). Kerns et al. (1999) evidenced that the phospholipase A₂ CM-IV in presence of factor Va inhibits thrombin formation by factor Xa. In order to evaluate the presence of other *Mtt* crude venom inhibitors, the activity of this venom was evaluated on thrombin and factor Xa amidolytic and coagulant activities. The results evidenced that *Mtt* venom (Tables 4 and 5) was capable of induce inhibition of the amidolytic activity and the coagulant activity of factor Xa in human plasma in presence of calcium. Thus factor Xa is the target protein of this anticoagulant present in *Mtt* venom. It was possible to identify a significant factor Xa inhibitory activity in *Mtt* venom; and therefore, studies must be continued at this level.

Osipov et al. (2010), isolated and characterized a phospholipase A₂ from *Naja haje* cobra venom, identified as TI-NH, which was the first direct thrombin inhibitor found in the venom of the Elapidae family and the first phospholipase with that function. Clinically, the specific inhibition of factor Xa or thrombin would reduce the risk of hemorrhagic syndromes.

This work constitutes, to our knowledge, the first report on fibrino(geno)lytic and inhibitors of plasmin and factor Xa activities in *Micrurus* venoms. These molecules, once purified and characterized, may be useful as therapeutic tools for thrombosis, strokes and other hemorrhagic diseases.

Acknowledgments

This research was supported by FONACIT grant (G-2005000400), Caracas, Venezuela, and funds from Texas A&M University-Kingsville, Kingsville, Texas, U.S.A.

References

- Aguilar I, Girón ME, Rodríguez-Acosta A. Purification and characterization of a hemorrhagic fraction from the venom of the Uracoan rattlesnake *Crotalus vegrandis*. *Biochim. Biophys. Acta.* 2001; 1548:57–65.
- Aird SD, da Silva NJ Jr. Comparative enzymatic composition of Brazilian coral snake (*Micrurus*) venoms. *Comp. Biochem. Physiol. B.* 1991; 99:287–294. [PubMed: 1662592]
- Alape-Girón A, Lomonte B, Gustafsson B, Da Silva NJ, Thelestam M. Electrophoretic and immunochemical studies of *Micrurus* snake venoms. *Toxicon.* 1994; 32:713–723. [PubMed: 7940577]
- Alape-Girón A, Persson B, Cederlund E, Flores-Díaz M, Gutiérrez JM, Thelestam M, Bergman T, Jörnvall H. Elapid venom toxins: multiple recruitments of ancient scaffolds. *Eur. J. Biochem.* 1999:225–234. [PubMed: 9914497]

- Arce V, Rojas E, Ownby CL, Rojas G, Gutiérrez JM. Preclinical assessment of the ability of polyvalent (Crotalinae) and anticoral (Elapidae) antivenoms produced in Costa Rica to neutralize the venoms of North American snakes. *Toxicon*. 2003; 41:851–860. [PubMed: 12782085]
- Banerjee Y, Mizuguchi J, Iwanaga S, Kini M. Hemextin AB complex - A snake venom anticoagulant protein complex that inhibits factor VIIa activity. *Pathophysiol. Haemost. Thromb*. 2005; 34:184–187. [PubMed: 16707924]
- Barros ACS, Fernandes DP, Ferreira LCL, Santos MC. Local effects induced by venoms from five species of genus *Micrurus* sp. (coral snakes). *Toxicon*. 1994; 32:445–452. [PubMed: 8052999]
- Bjarnason JB, Fox JW. Hemorrhagic metalloproteinases from snake venoms. *Pharmacol. Ther*. 1994; 62:325–372. [PubMed: 7972338]
- Braud S, Bon C, Wisner A. Snake venom proteins acting on hemostasis. *Biochimie*. 2000; 82:851–859. [PubMed: 11086215]
- Cecchini AL, Marcussi S, Silveira LB, Borja-Oliveira CR, Rodrigues-Simioni L, Amara S, Stabeli RG, Giglio JR, Arantes EC, Soares AM. Biological and enzymatic activities of *Micrurus* sp. (Coral) snake venoms. *Comp. Biochem. Physiol. Part A*. 2005; 140:125–134.
- Chester A, Crawford GP. *In vitro* coagulant properties of venoms from Australian snakes. *Toxicon*. 1982; 20:501–504. [PubMed: 7080056]
- Cho IH, Choi ES, Lim HG, Lee HH. Purification and characterization of six fibrinolytic serine-proteases from earthworm *Lumbricus rubellus*. *J. Biochem. Mol. Biol*. 2004; 37:199–205. [PubMed: 15469696]
- Daoud E, Tu AT, el-Asmar MF. Isolation and characterization of an anticoagulant proteinase, cerastase F-4, from *Cerastes cerastes* (Egyptian sand viper) venom. *Thromb. Res*. 1986; 42:55–62. [PubMed: 3010494]
- de Roodt AR, Paniagua-Solis JF, Dolab JA, Estévez-Ramírez J, Ramos-Cerrillo B, Litwin S, Dokmetjian JC, Alagón A. Effectiveness of two common antivenoms for North, central, and south American *Micrurus* envenomations. *J. Toxicol. Clin. Toxicol*. 2004; 42:171–178. [PubMed: 15214622]
- Dokmetjian JC, Del Canto S, Vinzón S, de Jiménez-Bonino MB. Biochemical characterization of the *Micrurus pyrrochryptus* venom. *Toxicon*. 2009; 53:375–382. [PubMed: 19135468]
- Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: a need for novel strategies. *Mol. Biosyst*. 2010; 6:305–315. [PubMed: 20094648]
- Francis BR, da Silva NJ Júnior, Seebart C, Casais E, Silva LL, Schmidt JJ, Kaiser II. Toxins isolated from the venom of the Brazilian coral snake (*Micrurus frontalis frontalis*) include hemorrhagic type phospholipases A2 and postsynaptic neurotoxins. *Toxicon*. 1997; 35:1193–1203. [PubMed: 9278969]
- Fry BG. Structure-function properties of venom components from Australian elapids. *Toxicon*. 1999; 37:11–32. [PubMed: 9920477]
- Gerads I, Tans G, Yukelson LYa, Zwaal RF, Rosing J. Activation of bovine factor V by an activator purified from the venom of *Naja naja oxiana*. *Toxicon*. 1992; 30:1065–1079. [PubMed: 1440644]
- Gowda CD, Nataraju A, Rajesh R, Dhananjaya BL, Sharath BK, Vishwanath BS. Differential action of proteases from *Trimeresurus malabaricus*, *Naja naja* and *Daboia russellii* venoms on hemostasis. *Comp. Biochem. Physiol. C. Toxicol. Pharmacol*. 2006; 143:295–302. [PubMed: 16627005]
- Gutiérrez JM, Lomonte B, Portilla E, Cerdas L, Rojas E. Local effects induced by coral snake venoms: evidence of myonecrosis after experimental inoculations of venoms from five species. *Toxicon*. 1983; 21:777–783. [PubMed: 6658805]
- Gutiérrez JM, Rojas G, Pérez A, Argüello I, Lomonte B. Neutralization of coral snake *Micrurus nigrocinctus* venom by a monovalent antivenom. *Braz. J. Med. Biol. Res*. 1991; 24:701–710. [PubMed: 1823287]
- Gutiérrez JM, Rojas G, da Silva Júnior NJ, Núñez J. Experimental myonecrosis induced by the venoms of South American *Micrurus* (coral snakes). *Toxicon*. 1992; 30:1299–1302. [PubMed: 1440634]
- Guerrero B, Arocha-Piñango CL. Activation of human prothrombin by the venom of *Lonomia achelous* (Cramer) caterpillars. *Thromb. Res*. 1992; 66:169–177. [PubMed: 1412190]

- Jagadeesha DK, Shashidhara-Murthy R, Girish KS, Kemparaju K. A non-toxic anticoagulant metalloprotease: purification and characterization from Indian cobra (*Naja naja naja*) venom. *Toxicon*. 2002; 40:667–675. [PubMed: 12175602]
- Kamiguti AS, Hay CRM, Theakston RDG, Zuzel M. Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. *Toxicon*. 1996; 34:627–642. [PubMed: 8817809]
- Kerns RT, Kini RM, Stefansson S, Evans HJ. Targeting of venom phospholipases: the strongly anticoagulant phospholipase A2 from *Naja nigricollis* venom binds to coagulation factor Xa to inhibit the prothrombinase complex. *Arch. Biochem. Biophys.* 1999; 369:107–113. [PubMed: 10462445]
- Kini RM, Evans HJ. Inhibition of platelet aggregation by a fibrinogenases from *Naja nigricollis* venom is independent of fibrinogen degradation. *Biochim. Biophys. Acta*. 1991; 1095:117–121. [PubMed: 1932133]
- Kini RM, Evans HJ. Structural domains in venom proteins: evidence that metalloproteinases and non-enzymatic platelet aggregation inhibitors (Disintegrins) from the snake venoms are derived by proteolysis from a common precursor. *Toxicon*. 1992; 30:265–293. [PubMed: 1529462]
- Kini RM. Serine proteases affecting blood coagulation and fibrinolysis from snake venoms. *Pathophysiol. Haemost. Thromb.* 2005; 34:200–204. [PubMed: 16707928]
- Kumar MS, Devaraj VR, Vishwanath BS, Kemparaju K. Anticoagulant activity of a metalloprotease: further characterization from the Indian cobra (*Naja naja*) venom. *J Thromb. Thrombolysis*. 2010; 29:340–348. [PubMed: 19629641]
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J. Biol. Chem.* 1951; 1193:265–275. [PubMed: 14907713]
- Markland FS. Snake Venoms and the Hemostatic System. *Toxicon*. 1998; 36:1749–1800. [PubMed: 9839663]
- Marsh NA, Arocha-Piñango CL. Evaluation of the fibrin plate method for estimating plasminogen activators. *Thromb. Diath. Haemorrh.* 1972; 28:75–88. [PubMed: 4672652]
- Maruyama M, Suzuki M, Yoshida E, Mihara H, Nakajima N. Purification and characterization of two fibrinolytic enzymes from *Bothrops jararaca* (Jararaca) venom. *Toxicon*. 1992; 30:853–864. [PubMed: 1523677]
- Masci PP, Whitaker AN, Sparrow LG, de Jersey J, Winzor DJ, Watters DJ, Lavin MF, Gaffney PJ. Textilins from *Pseudonaja textilis textilis*. Characterization of two plasmin inhibitors that reduce bleeding in an animal model. *Blood. Coagul. Fibrinolysis*. 2000;385–393. [PubMed: 10847427]
- Matsui T, Fujimura Y, Titani K. Snake venom proteases affecting hemostasis and thrombosis. *Biochim. Biophys. Acta*. 2000; 1477:146–156. [PubMed: 10708855]
- Millers EK, Trabi M, Masci PP, Lavin MF, de Jersey J, Guddat LW. Crystal structure of textilinin-1, a Kunitz-type serine protease inhibitor from the venom of the Australian common brown snake (*Pseudonaja textilis*). *FEBS. J.* 2009; 276:3163–3175. [PubMed: 19490116]
- Moran JB, Geren CR. Characterization of a fibrinogenase from northern copperhead (*Agkistrodon contortrix mokasen*) venom. *Biochim. Biophys. Acta*. 1981; 659:161–168. [PubMed: 6788089]
- NIH. Principles of Laboratory Animal Care. Vol. vol. 85. USA: National Institute of Health; 1985. p. 1-112.
- Nishida S, Fujimura Y, Miura S, Ozaki Y, Usami Y, Suzuki S, Titán K, Yoshida E, Sugimoto M, Yoshioka A, Fukui H. Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of *Bothrops jararaca*. *Biochemistry*. 1994; 33:1843–1849. [PubMed: 8110787]
- Osipov AV, Filkin SY, Makarova YV, Tsetlin VI, Utkin YN. A new type of thrombin inhibitor, noncytotoxic phospholipase A2, from the *Naja naja* cobra venom. *Toxicon*. 2010:186–194. [PubMed: 19622365]
- Oyama E, Takahashi H. Distribution of low molecular weight platelet aggregation inhibitors from snake venoms. *Toxicon*. 2007; 49:293–298. [PubMed: 17141819]
- Rao VS, Swarup S, Kini RM. The non-enzymatic subunit of pseutarin C, a prothrombin activator from eastern brown snake (*Pseudonaja textilis*) venom, shows structural similarity to mammalian coagulation factor V. *Blood*. 2003; 102:1347–1354. [PubMed: 12730119]

- Rengifo, C.; Rodríguez-Acosta, A. Serpientes, venenos y su tratamiento en Venezuela. 1er ed.. Caracas: Fondo de Publicaciones de la Facultad de Medicina de la Universidad Central de Venezuela; 2004. p. 1-86.
- Ritonja A, Turk V, Gubensek F. Serine proteinase inhibitors from *Vipera ammodytes* venom. Isolation and kinetic studies. *Eur. J. Biochem.* 1983; 133:427–432. [PubMed: 6602050]
- Rosso JP, Vargas-Rosso O, Gutiérrez JM, Rochat H, Bougis PE. Characterization of alpha-neurotoxin and phospholipase A2 activities from *Micrurus* venoms. Determination of the amino acid sequence and receptor-binding ability of the major alpha-neurotoxin from *Micrurus nigrocinctus nigrocinctus*. *Eur. J. Biochem.* 1996; 238:231–239. [PubMed: 8665942]
- Roze, JA. Coral Snakes of the Americas: Biology, Identification, and Venoms. Malabar: Krieger Publishing Company; 1996. p. 1-340.
- Sakurai Y, Takatsuka H, Yoshioka A, Matsui T, Suzuki M, Titani K, Fujimura Y. Inhibition of human platelet aggregation by L-amino acid oxidase purified from *Naja naja kaouthia* venom. *Toxicon.* 2001; 39:1827–1833. [PubMed: 11600144]
- Salazar AM, Rodríguez-Acosta A, Girón ME, Aguilar I, Guerrero B. A comparative analysis of the clotting and fibrinolytic activities of the mapanare (*Bothrops atrox*) snake venom from different geographical areas in Venezuela. *Thromb. Res.* 2007; 120:95–104. [PubMed: 17045631]
- Sánchez EE, Lopez-Johnston JC, Rodríguez-Acosta A, Pérez JC. Neutralization of two North American coral snake venoms with United States and Mexican antivenoms. *Toxicon.* 2008; 51:297–303. [PubMed: 18054059]
- Satish S, Tejaswini J, Krishnakantha TP, Gowda TV. Purification of a Class B1 platelet aggregation inhibitor phospholipase A2 from Indian cobra (*Naja Naja*) venom. *Biochimie.* 2004; 86:203–210. [PubMed: 15134835]
- Stefansson S, Kini RM, Evans HJ. The basic phospholipase A2 from *Naja nigricollis* venom inhibits the prothrombinase complex by a novel nonenzymatic mechanism. *Biochemistry.* 1990; 29:7742–7746. [PubMed: 2271532]
- St Pierre L, Masci PP, Filippovich I, Sorokina N, Marsh N, Miller DJ, Lavin MF. Comparative analysis of prothrombin activators from the venom of Australian elapids. *Mol. Biol. Evol.* 2005; 22:1853–1864. [PubMed: 15930152]
- Stoscheck CM. Quantitation of protein. *Methods Enzymol.* 1990; 182:50–68. [PubMed: 2314256]
- Sundell IB, Rånby M, Zuzel M, Robinson KA, Theakston RD. *In vitro* procoagulant and anticoagulant properties of *Naja naja naja* venom. *Toxicon.* 2003; 42:239–247. [PubMed: 14559074]
- Suntravat M, Nuchprayoon I, Pérez JC. Comparative study of anticoagulant and procoagulant properties of 28 snake venoms from families Elapidae, Viperidae, and purified Russell's viper venom-factor X activator (RVV-X). *Toxicon.* 2010; 56:544–553. [PubMed: 20677373]
- Swenson S, Markland FS. Snake venom fibrin(ogen)olytic enzymes. *Toxicon.* 2005; 45:1021–1039. [PubMed: 15882884]
- Takahashi H, Iwanaga S, Kitagawa T, Hokama Y, Suzuki T. Snake venom proteinase inhibitors. Chemical structure of inhibitor II isolated from the venom of Russell's viper (*Viper russelli*). *J. Biochem.* 1974; 76:721–733. [PubMed: 4436285]
- Tanaka GD, Furtado MF, Portaro FC, Sant'Anna OA, Tambourgi DV. Diversity of *Micrurus* snake species related to their venom toxic effects and the prospective of antivenom neutralization. *PLoS Negl Trop. Dis.* 2010; 4:e622. [PubMed: 20231886]
- Urdaneta AH, Bolaños F, Gutiérrez JM. Feeding behavior and venom toxicity of coral snake *Micrurus nigrocinctus* (Serpentes: Elapidae) on its natural prey in captivity. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* 2004; 138:485–492. [PubMed: 15536056]
- Utkin YN, Osipov AV. Non-Lethal Polypeptide components in cobra venom. *Current. Pharmaceutical. Design.* 2007; 13:2906–2915.
- Varon D, Shai E, Spectre G. Frontiers in platelet inhibition. *Discov. Med.* 2009; 8:242–246. [PubMed: 20040278]
- White J. Snake venoms and coagulopathy. *Toxicon.* 2005; 45:951–967. [PubMed: 15922768]
- Wijeyewickrema LC, Gardiner EE, Shen Y, Berndt MC, Andrews RK. Fractionation of snake venom metalloproteinases by metal ion affinity: a purified cobra metalloproteinase Nk, from *Naja kaouthia* binds Ni²⁺-agarose. *Toxicon.* 2007; 50:1064–1072. [PubMed: 17822731]

- World Health Organization. Vol. 58. Geneva: WHO Offset Publication; 1981. Progress in the Characterization of Venoms and Standardization of Antivenoms.
- Zaganelli GL, Zaganelli MGM, Magalhaes A, Diniz CR, de Lima ME. Purification and characterization of fibrinogenase from the venom of Jararacucu (*Bothrops jararacussu*). *Toxicon*. 1996; 34:807–819. [PubMed: 8843581]
- Zhang Y, Wisner A, Xiong Y, Bon C. A novel plasminogen activator from snake venom. Purification, characterization, and molecular cloning. *J. Biol. Chem.* 1995; 270:10246–10255. [PubMed: 7730329]
- Zingali RB, Jandrot-Perrus M, Guillén MC, Bon C. Bothrojaracin, a new thrombin inhibitor isolated from *Bothrops jararaca* venom: characterization and mechanism of thrombin inhibition. *Biochemistry*. 1993; 32:10794–10802. [PubMed: 8399228]




Fig. 1. An 10–20% SDS-PAGE of *M. t. tener* (*Mtt*) crude venom. Lanes: 1) Molecular weight markers; 2) *Mtt* (50 μ g) under non-reducing conditions; 3) *Mtt* (50 μ g) under reducing conditions. The gel was stained with Simply blue.




Fig. 2. Molecular exclusion chromatographic profile of *M. t. tener* venom. Crude venom (5 mg) was reconstituted in 100 μ l of 50 mM ammonium acetate buffer, pH 6.9 and fractionated through a Superdex-200 column (10 \times 300 mm) previously equilibrated with the same buffer. The venom was run for 80 min at 0.4 ml/min, and the proteins were detected at 280 nm. The insert shows the fractions F1–F5, which showed the fractions with a high anti ADP-inducer-platelet aggregation and anti-plasmin activities.




Fig. 3. Fibrinogenolytic activity of *M. t. tener* (*Mtt*) crude venom. A) A ratio of 100 μ g of fibrinogen (Fg):1 μ g venom was incubated at 37 °C at different times. Lanes: 1) Molecular weight markers; 2) Fg control (25 μ g); 3 – 8) Fg + *Mtt* at 5 min, 1, 2, 4, 18 and 24 h, respectively; 9) crude venom (15 μ g). B) A ratio of 100 μ g Fibrinogen (Fg):1 μ g venom was incubated in presence of protease inhibitors, for 2 h at 37 °C. Lanes: 1) Molecular weight markers; 2) 25 μ g Fg control; 3) Fg + *Mtt*; 4) Fg + (*Mtt* + EDTA); 5) Fg + (*Mtt* + EGTA); 6) Fg + (*Mtt* + Benzamidine); 7) Fg + (*Mtt* + Aprotinin); 8) Fg + (*Mtt* + Iodoacetic acid). An 8% SDS-PAGE under reduced conditions was used and stained with Coomassie blue.




Fig. 4. Fibrinogenolytic activity of *M. t. tener* chromatographic venom fractions. A) A ratio of 100 μ g fibrinogen (Fg):1 μ g fraction was incubated for 24 h at 37 °C. A. Lanes: 1) Molecular weight markers; 2 – 11) Fg control at 24 h; 3–11) Fg + fractions F1, F2, F3, F4, F5, F7, F8, and F9, respectively. B) Fibrinolytic activity of fractions in presence of protease inhibitors. Lanes: 1) Molecular weight markers; 2) Fg control at 24 h; 3) Fg + F3; 4) Fg + (F3 + SPI); 5) Fg + (F3 + MPI); 6) Fg + (F3 + CPI); 7) Fg + F7; 8) Fg + (F7 + SPI); 9) Fg+(F7 + MPI); 10) Fg+(F7 + CPI); 11) Fg+(F7+SPI+MPI). An 8% SDS-PAGE was used under reduced conditions and stained with Coomassie blue.




Fig. 5. Fibrinolytic activity on fibrin plates (in presence of plasminogen) observed with *M. t. tener* (*Mtt*) crude venom. A) 0.125 nKcat plasmin; B) *Mtt* (25 µg); C) *Mtt* (50 µg). The arrows point to the plasmin inhibition halo.




Fig. 6. The effects of *M. t. tener* crude venom on plasmin fibrinolytic activity evaluated in micro-plates. (PL: plasmin; Mtt: *M. t. tener* venom; BZ: benzamidine; IA: Iodoacetic acid; EDTA: ethylenediaminetetraacetic acid).

Table 1LD₅₀s of Venezuelan and United States coral snake venoms.

Species	Pool	LD ₅₀ ^a ± SD (mg/kg)
<i>M. isozonus</i>	La Boyera, Miranda state (Venezuela)	0.56 ± 0.072
<i>M. isozonus</i>	Caracas, Capital District (Venezuela)	0.52 ± 0.090
<i>M. isozonus</i>	Calabozo, Guárico state (Venezuela)	0.61 ± 0.086
<i>M. isozonus</i>	Maracay, Aragua state (Venezuela)	0.58 ± 0.080
<i>M. tener tener</i>	Kingsville, Texas state (United States)	0.78 ± 0.140
<i>M. fulvius fulvius</i>	Tampa, Florida state (United States)	0.32 ± 0.120 (<i>p</i> < 0.05)

^aThe LD₅₀ is the concentration of venom required to kill 50% of a mouse population (*n* = 40/group) after 48 h. Results are expressed in mg venom/kg body weight.

Table 2

The effects of coral snake venoms (10 μ g) on ADP-induced platelet aggregation.

Venoms	% Inhibition ^a
<i>M. isozonus</i> , La Boyera, Miranda state (Venezuela)	54.8 \pm 5.2
<i>M. isozonus</i> , Calabozo, Guárico state (Venezuela)	50.1 \pm 6.4
<i>M. isozonus</i> , Maracay, Aragua state (Venezuela)	55.9 \pm 8.0
<i>M. isozonus</i> , Caracas, Capital District, (Venezuela)	68.2 \pm 10.2
<i>M. tener tener</i> , Kingsville, Texas state (United States)	95.2 \pm 13.3 * ($p < 0.05$)
<i>M. fulvius fulvius</i> , Tampa, Florida state (United States)	60.3 \pm 8.9

* $p < 0.05$ in comparison with other venoms.

^aThe activity is expressed in percentage inhibition. The maximum aggregation response obtained after addition of inducer in presence of PBS was taken as 100% aggregation.

Table 3

The effects of *Micrurus t. tener* molecular exclusion fractions on hemostatic functions.

Fractions or CV	Mr kDa ^a	Activity	% Anti-Platelet aggregation (ADP) (10 µg)	α Fibrinogenase ^b	α/β Fibrinogenase	Fibrinolytic ^{e,f}	% Anti-Plasmin (S-2251) (20 µg)
CV			95.2	+	-	+	71.3
F1			86.3	+	+ ^c	+	-
F2			-	+	-	+	66.2
F3			-	+	-	+	-
F4			-	-	-	+	-
F5	>158.000		61.1	-	-	-	47.9
F6	73.147		70.2	+	+ ^d	-	74.8
F7	26.678		60.0	+	-	+	41.4
F8	15.814		-	+	-	+	81.1
F9	12.095		-	-	-	-	41.6
F10	<5.000		87.2	-	-	-	-
F11			51.9	-	-	-	-
F12			80.3	-	-	-	-
F13			84.6	-	-	-	37.3
F14			81.7	-	-	-	81.9
F15			61.2	-	-	-	62.4
F16							

+: Active; -: Inactive.

^a Relative molecular mass determinate by molecular exclusion chromatography.

^b Activity abolished by metalloprotease inhibitor (MPI).

^c Activity abolished by MPI inhibitor.

^d Activity abolished partially inhibited by EDTA, serine protease inhibitor (SPI) and/or iodoacetic acid.

^e Activity abolished by MPI plus serine protease inhibitors.

^f Activity determinate by fibrin plate using micro-plate method.

Table 4

The effects of coral snake venom on plasmin, factor Xa and thrombin amidolytic activities.

Venoms (20 ug)	% Inhibition		
	Plasmin (0.25 nKcat) S-2251	Factor Xa (0.05 IU) S-2222	Thrombin (0.1 IU) S-2238
<i>M. isozonus</i> La Boyera, Miranda state (Venezuela)	56.8 ± 7.2	16.5 ± 2.7	6.5 ± 0.72
<i>M. isozonus</i> Calabozo, Guárico state (Venezuela)	52.5 ± 5.5	21.6 ± 2.8	8.3 ± 1.0
<i>M. isozonus</i> Maracay, Aragua state (Venezuela)	49.2 ± 5.1	17.4 ± 2.0	7.8 ± 0.5
<i>M. isozonus</i> Caracas, Capital District, (Venezuela)	98.5 ± 10.2 (p < 0.05)	21.0 ± 2.6	10.1 ± 1.6
<i>M. tener tener</i> Kingsville, Texas state (United States)	71.3 ± 6.9	0	0
<i>M. fulvius fulvius</i> Tampa, Florida state (United States)	39.8 ± 4.0	0	1.4 ± 0.7

Table 5

The effects of *M. t. tener* crude venom on factor Xa and thrombin coagulant activity.

Venom (μg)	Thrombin (2.5 IU/mL)		Factor Xa (0.05 IU/mL)
	Plasma Coagulation	Fibrinogen Time (s)	Human Plasma (in presence of CaCl_2)
0	39.9 ± 0.14	31.1 ± 0.14	20.8 ± 0.55
1	35.3 ± 0.14	18.8 ± 1.13	27.9 ± 0.14
5	29.4 ± 0.14	15.1 ± 0.14	58.5 ± 0.71
25	20.4 ± 0.56	13.7 ± 0.14	251.0 ± 1.41